Hi Mark

This is a draft contract for your perusal.

The IP plan has not been finalised yet.

The main concerns for the PGGRC I think are the use of AbM4 for testing hits that are found in the screening by Auckland (using Mcr) and that the intention is to include a statement saying that PGGRC would have first rights to any useful molecules out of the programme. At the moment MPI would own the IP and Auckland and AgResearch investigators would be co-inventors. As discussed the 96-well AbM4 plate method has been published and the genome for AbM4 has been published as well.

Any comments would be much appreciated.

Ron
